IDEX-Compared to Estimates, Idex (IEX) Q4 Earnings: A Look at Key Metrics

Core Insights - Idex (IEX) reported revenue of $862.9 million for the quarter ended December 2024, marking a year-over-year increase of 9.4% and an EPS of$ 2.04 compared to $1.83 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of$ 864.97 million by 0.24%, while the EPS exceeded the consensus estimate of $2.03 by 0.49% [1] Financial Performance Metrics - Organic net sales growth was 3%, slightly below the two-analyst average estimate of 3.7% [4] - Net Sales in Fluid & Metering Technologies (FMT) were reported at$ 299.30 million, lower than the average estimate of $315.03 million, reflecting a year-over-year change of +0.1% [4] - Net Sales in Fire & Safety/Diversified Products (FSDP) reached$ 192.90 million, surpassing the average estimate of $190.13 million, with a year-over-year increase of +7.8% [4] - Health & Science Technologies (HST) net sales were$ 373.20 million, exceeding the average estimate of $360.84 million, representing a +19.4% change year-over-year [4] Adjusted EBITDA Analysis - Adjusted EBITDA for Fluid & Metering Technologies (FMT) was$ 94.70 million, below the average estimate of $101 million [4] - Adjusted EBITDA for Corporate was reported at -$ 20.10 million, better than the average estimate of - $21.95 million [4] - Adjusted EBITDA for Fire & Safety/Diversified Products (FSDP) was$ 54.30 million, slightly above the average estimate of $53.40 million [4] - Adjusted EBITDA for Health & Science Technologies (HST) was$ 98.60 million, lower than the average estimate of $101.95 million [4] Stock Performance - Idex shares have returned +4.6% over the past month, outperforming the Zacks S&P 500 composite's +1% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]